- In April 2023, Chimeric Therapeutics, an oncology-focused biotech company, announced the advancement of its CHM 2101 program, a novel CAR T-cell therapy targeting solid tumors, including chordoma. The therapy, which is based on chlorotoxin targeting IL13Rα2, entered preclinical development stages with promising anti-tumor activity. This progress highlights Chimeric’s commitment to developing next-generation immunotherapies for rare and hard-to-treat cancers, marking a significant step toward cell-based treatments in the chordoma landscape
- In March 2023, the Chordoma Foundation launched a global patient registry in collaboration with multiple clinical institutions, aimed at accelerating research and improving treatment protocols for chordoma patients. This initiative facilitates real-world data collection on patient outcomes, enabling more informed clinical decisions and fostering collaboration between researchers, healthcare providers, and pharmaceutical companies. The registry exemplifies the growing role of patient-centered data in guiding treatment innovations
- In February 2023, Novartis AG announced new clinical trial data on its investigational tyrosine kinase inhibitor for rare tumors, including chordoma. Preliminary results demonstrated favorable safety and efficacy profiles, reinforcing Novartis’ role in developing targeted treatments for niche oncology markets. This development emphasizes the potential of kinase inhibitors in managing advanced or inoperable chordoma cases
- In January 2023, OncoFusion Therapeutics, a biotech company specializing in fusion gene-driven cancers, initiated preclinical research on a new small molecule therapy specifically designed to target the brachyury gene, which is uniquely overexpressed in chordoma. The company’s work represents a promising direction for personalized therapy development and aligns with the growing demand for gene-targeted treatments in rare cancers
- In January 2023, Radiation Oncology Centers in the U.S. and Europe, including the Mayo Clinic and Heidelberg Ion-Beam Therapy Center, reported advancements in proton and carbon ion therapy protocols for chordoma. These cutting-edge radiation therapies offer higher precision and reduced side effects, making them increasingly preferred for tumors located near critical neurological structures. Such developments underscore the ongoing shift toward more effective and less invasive treatment options in the global chordoma care ecosystem
